| review article | Q7318358 |
| scholarly article | Q13442814 |
| P8150 | COVIDWHO ID | covidwho-176029 |
| P6179 | Dimensions Publication ID | 1127379782 |
| P356 | DOI | 10.1016/J.DSX.2020.04.040 |
| P932 | PMC publication ID | 7198998 |
| P698 | PubMed publication ID | 32388330 |
| P8299 | Semantic Scholar corpus ID | 218488475 |
| P2093 | author name string | Naim Shehadeh | |
| Afif Nakhleh | |||
| P2860 | cites work | A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 | Q24290169 |
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury | Q28260798 | ||
| Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells | Q28538745 | ||
| High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes | Q28582700 | ||
| Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion | Q34706863 | ||
| Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes | Q35184167 | ||
| Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells | Q35572580 | ||
| Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice | Q35757097 | ||
| Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients | Q35912987 | ||
| Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice | Q36477252 | ||
| Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry | Q36693984 | ||
| Early versus late intravenous insulin administration in critically ill patients | Q36793810 | ||
| Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis | Q37101896 | ||
| The sweeter side of ACE2: physiological evidence for a role in diabetes | Q37178255 | ||
| Diabetes, insulin, and development of acute lung injury | Q37521491 | ||
| Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice | Q37629192 | ||
| Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse | Q37729150 | ||
| A Protective Role of Glibenclamide in Inflammation-Associated Injury. | Q39455583 | ||
| Corrigendum to "Metformin-associated lactic acidosis: Current perspectives on causes and risk" [Metabolism 65 (2016) 20-29] | Q87683763 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway | Q89753541 | ||
| DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice | Q91315722 | ||
| Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill | Q91738423 | ||
| COVID-19: immunopathology and its implications for therapy | Q91788035 | ||
| Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China | Q91803054 | ||
| Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 | Q91807337 | ||
| The metalloprotease ADAM17 in inflammation and cancer | Q93136729 | ||
| Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 | Q93221320 | ||
| Practical recommendations for the management of diabetes in patients with COVID-19 | Q93227089 | ||
| The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus | Q95522550 | ||
| Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury | Q39935785 | ||
| Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists! | Q41886708 | ||
| Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. | Q43251946 | ||
| Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes | Q46068140 | ||
| Recombinant human ACE2: acing out angiotensin II in ARDS therapy | Q47107315 | ||
| Angiotensin-converting enzyme 2 protects from severe acute lung failure | Q47768368 | ||
| Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment | Q50032772 | ||
| High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. | Q51349140 | ||
| ACE2 deficiency shifts energy metabolism towards glucose utilization. | Q51676579 | ||
| GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway. | Q55306779 | ||
| Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. | Q55641730 | ||
| Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios | Q58772421 | ||
| Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats | Q60559888 | ||
| Glibenclamide alleviates inflammation in oleic acid model of acute lung injury through NLRP3 inflammasome signaling pathway | Q64063617 | ||
| Insulin attenuates endotoxin-induced acute lung injury in conscious rats | Q82677756 | ||
| P433 | issue | 4 | |
| P921 | main subject | COVID-19 | Q84263196 |
| P304 | page(s) | 509-512 | |
| P577 | publication date | 2020-05-05 | |
| P1433 | published in | Diabetes and Metabolic Syndrome: Clinical Research and Reviews | Q15816957 |
| P1476 | title | Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review | |
| P478 | volume | 14 |
| Q98944137 | A protein interaction map identifies existing drugs targeting SARS-CoV-2 |
| Q96817963 | COVID-KOP: Integrating Emerging COVID-19 Data with the ROBOKOP Database |
| Q101567527 | COVID-KOP: Integrating Emerging COVID-19 Data with the ROBOKOP Database |
Search more.